Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 216

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group

Open access
Amoaku, Winfried M., Ghanchi, Faruque, Bailey, Clare, Banerjee, Sanjiv, Banerjee, Somnath, Downey, Louise, Gale, Richard, Hamilton, Robin, Khunti, Kamlesh, Posner, Esther, Quhill, Fahd, Robinson, Stephen, Setty, Roopa, Sim, Dawn, Varma, Deepali, Mehta, Hemal·2020·Eye

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41433-020-0961-6

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Research works printed but not linked: 441

  1. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology. 1998;105:1801–15. · DOI · Paper page
  2. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82:844–51.
  3. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic Macular Edema: Pathogenesis and Treatment. Survey of Ophthalmology. 2009;54:1–32. · DOI · Paper page
  4. Abbate M, Cravedi P, Iliev I, Remuzzi G, Ruggenenti P. Prevention and Treatment of Diabetic Retinopathy: Evidence from Clinical Trials and Perspectives. Current Diabetes Reviews. 2011;7:190–200. · DOI
  5. Heng LZ, Comyn O, Peto T, Tadros C, Ng E, Sivaprasad S, et al. Diabetic retinopathy: pathogenesis, clinical grading, management and future developments. Diabetic Medicine. 2013;30:640–50. · DOI · Paper page
  6. Hendrick AM, Gibson MV, Kulshreshtha A. Diabetic Retinopathy. Primary Care: Clinics in Office Practice. 2015;42:451–64. · DOI · Paper page
  7. Colucciello M. Current intravitreal pharmacologic therapies for diabetic macular edema. Postgraduate Medicine. 2015;127:640–53. · DOI
  8. Gangwani RA, Lian JX, McGhee SM, Wong D, Li KK. Diabetic retinopathy screening: global and local perspective. Hong Kong Med J. 2016;22:486–95.
  9. Semeraro F, Morescalchi F, Cancarini A, Russo A, Rezzola S, Costagliola C. Diabetic retinopathy, a vascular and inflammatory disease: Therapeutic implications. Diabetes Metab. 2019;45:517–27. · DOI · Paper page
  10. Doft BH, Kingsley LA, Orchard TJ, Kuller L, Drash A, Becker D. The Association Between Long-term Diabetic Control and Early Retinopathy. Ophthalmology. 1984;91:763–9. · doi:10.1016/s0161-6420(84)34235-x
  11. Kollias AN, Ulbig MW. Diabetic retinopathy: Early diagnosis and effective treatment. Dtsch Arztebl Int. 2010;107:75–83. quiz 84
  12. Thomas RL, Luzio SD, North RV, Banerjee S, Zekite A, Bunce C, et al. Retrospective analysis of newly recorded certifications of visual impairment due to diabetic retinopathy in Wales during 2007-2015. BMJ Open. 2017;7:e015024. · DOI
  13. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237:185–222. · DOI · Paper page
  14. Kodjikian L, Bellocq D, Bandello F, Loewenstein A, Chakravarthy U, Koh A, et al. First-line treatment algorithm and guidelines in center-involving diabetic macular edema. Eur J Ophthalmol. 2019;29:573–84. · DOI
  15. International Diabetes Federation. IDF Atlas, 3rd Edition. 2006. https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/22-atlas-3rdedition.html.
  16. Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol. 2012;96:614–8. · DOI · Paper page
  17. International Diabetes Federation. IDF Atlas, 9th Edition. 2019. https://www.diabetesatlas.org/en/resources/.
  18. Makaroff LE, Cavan D. Which biochemical assay is best for measuring diabetes prevalence? Lancet Diabetes Endocrinol. 2015;3:582–3. · doi:10.1016/s2213-8587(15)00203-x
  19. Holman N, Forouhi NG, Goyder E, Wild SH. The Association of Public Health Observatories (APHO) Diabetes Prevalence Model: estimates of total diabetes prevalence for England, 2010-2030. Diabet Med. 2011;28:575–82. · DOI
  20. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet (London, England). 2010;376:124–36. · DOI · Paper page
  21. Huang OS, Tay WT, Ong PG, Sabanayagam C, Cheng CY, Tan GS, et al. Prevalence and determinants of undiagnosed diabetic retinopathy and vision-threatening retinopathy in a multiethnic Asian cohort: the Singapore Epidemiology of Eye Diseases (SEED) study. Br J Ophthalmol. 2015;99:1614–21. · DOI
  22. Williams R, Airey M, Baxter H, Forrester J, Kennedy-Martin T, Girach A. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye (Lond). 2004;18:963–83. · DOI · Paper page
  23. Raman R, Ganesan S, Pal SS, Gella L, Kulothungan V, Sharma T. Incidence and Progression of Diabetic Retinopathy in Urban India: Sankara Nethralaya-Diabetic Retinopathy Epidemiology and Molecular Genetics Study (SN-DREAMS II), Report 1. Ophthalmic Epidemiol. 2017;24:294–302. · DOI
  24. Melo LGN, Morales PH, Drummond KRG, Santos DC, Pizarro MH, Barros BSV, et al. Current epidemiology of diabetic retinopathy in patients with type 1 diabetes: a national multicenter study in Brazil. BMC Public Health. 2018;18:989.
  25. Rema M, Premkumar S, Anitha B, Deepa R, Pradeepa R, Mohan V. Prevalence of diabetic retinopathy in urban India: the Chennai Urban Rural Epidemiology Study (CURES) eye study, I. Invest Ophthalmol Vis Sci. 2005;46:2328–33. · DOI · Paper page
  26. Wong TY, Cheung N, Tay WT, Wang JJ, Aung T, Saw SM, et al. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. Ophthalmology. 2008;115:1869–75. · DOI · Paper page
  27. Xie XW, Xu L, Wang YX, Jonas JB. Prevalence and associated factors of diabetic retinopathy. The Beijing Eye Study 2006. Graefes Arch Clin Exp Ophthalmol. 2008;246:1519–26. · DOI
  28. Raymond NT, Varadhan L, Reynold DR, Bush K, Sankaranarayanan S, Bellary S, et al. Higher prevalence of retinopathy in diabetic patients of South Asian ethnicity compared with white Europeans in the community: a cross-sectional study. Diabetes Care. 2009;32:410–5. · DOI
  29. Tapp RJ, Shaw JE, Harper CA, de Courten MP, Balkau B, McCarty DJ, et al. The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care. 2003;26:1731–7. · DOI · Paper page
  30. Wang FH, Liang YB, Zhang F, Wang JJ, Wei WB, Tao QS, et al. Prevalence of diabetic retinopathy in rural China: the Handan Eye Study. Ophthalmology. 2009;116:461–7. · DOI · Paper page
  31. Klein R The epidemiology of diabetic retinopathy. In: Duh E editor. Diabetic retinopathy. Humana Press: Totowa, NJ; 2008. pp 67–108. · DOI
  32. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009;116:497–503. · DOI · Paper page
  33. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115:1859–68. · DOI · Paper page
  34. Jones CD, Greenwood RH, Misra A, Bachmann MO. Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England. Diabetes Care. 2012;35:592–6. · DOI
  35. Diabetes C, Complications Trial Research G, Nathan DM, Genuth S, Lachin J, Cleary P, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86. · DOI · Paper page
  36. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. Arch Ophthalmol. 1995;113:36–51. · DOI · Paper page
  37. Kohner EM, Aldington SJ, Stratton IM, Manley SE, Holman RR, Matthews DR, et al. United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch Ophthalmol. 1998;116:297–303. · DOI · Paper page
  38. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837–53. · DOI · Paper page
  39. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet (London, England). 1998;352:854–65. · DOI · Paper page
  40. Wong TY, Mwamburi M, Klein R, Larsen M, Flynn H, Hernandez-Medina M, et al. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care. 2009;32:2307–13. · DOI · Paper page
  41. Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM, Group UKPDS. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol. 2004;122:1631–40. · DOI · Paper page
  42. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23(Suppl 2):B54–64.
  43. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet (London, England). 2008;372:1394–402. · DOI · Paper page
  44. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet (London, England). 1998;351:28–31. · DOI · Paper page
  45. Beulens JW, Patel A, Vingerling JR, Cruickshank JK, Hughes AD, Stanton A, et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia. 2009;52:2027–36. · DOI · Paper page
  46. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet (London, England). 2005;366:1849–61. · DOI · Paper page
  47. Gale R, Scanlon PH, Evans M, Ghanchi F, Yang Y, Silvestri G, et al. Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease. Eye (Lond). 2017;31(S1):S1–S20. · DOI
  48. Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16–64 years), 1999–2000 with 2009–2010. BMJ Open. 2014;4:e004015. · DOI · Paper page
  49. Chang P-Y, Carrel H, Huang J-S, Wang I-J, Hou Y-C, Chen W-L, et al. Decreased density of corneal basal epithelium and subbasal corneal nerve bundle changes in patients with diabetic retinopathy. Am J Ophthalmol. 2006;142:488–90. · doi:10.1016/j.ajo.2006.04.033
  50. Malik RA, Kallinikos P, Abbott CA, van Schie CH, Morgan P, Efron N, et al. Corneal confocal microscopy: a non-invasive surrogate of nerve fibre damage and repair in diabetic patients. Diabetologia. 2003;46:683–8. · DOI · Paper page
  51. Midena E, Brugin E, Ghirlando A, Sommavilla M, Avogaro A. Corneal Diabetic Neuropathy: A Confocal Microscopy Study. Journal of Refractive Surgery. 2006;22:S1047–S1052. · DOI
  52. Mocan MC, Durukan I, Irkec M, Orhan M. Morphologic alterations of both the stromal and subbasal nerves in the corneas of patients with diabetes. Cornea. 2006;25:769–73. · doi:10.1097/01.ico.0000224640.58848.54
  53. Tavakoli M, Malik RA. Corneal confocal microscopy: a novel non-invasive technique to quantify small fibre pathology in peripheral neuropathies. J Vis Exp. 2011;2194. · DOI
  54. Tavakoli M, Petropoulos IN, Malik RA. Assessing corneal nerve structure and function in diabetic neuropathy. Clin Exp Optom. 2012;95:338–47. · DOI
  55. Zhivov A, Winter K, Hovakimyan M, Peschel S, Harder V, Schober HC, et al. Imaging and quantification of subbasal nerve plexus in healthy volunteers and diabetic patients with or without retinopathy. PLoS One. 2013;8:e52157. · DOI
  56. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol. 1984;102:527–32. · DOI · Paper page
  57. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1989;107:237–43. · DOI · Paper page
  58. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet (London, England). 1998;352:837–53. · DOI · Paper page
  59. Klein R, Marino EK, Kuller LH, Polak JF, Tracy RP, Gottdiener JS, et al. The relation of atherosclerotic cardiovascular disease to retinopathy in people with diabetes in the Cardiovascular Health Study. Br J Ophthalmol. 2002;86:84–90. · DOI
  60. Bhavsar AR. Diabetic retinopathy: the latest in current management. Retina. 2006;26(Supplement):S71–S79. · doi:10.1097/00006982-200607001-00016
  61. Bhavsar AR, Tornambe PE. 25 Years of Progress in the Treatment of Retinal Diseases: Where We Have Been, Where We Are Now, and Where We Will Be. Retina. 2006;26(Suppl):S1–S6. · DOI
  62. Han J, Lando L, Skowronska-Krawczyk D, Chao DL. Genetics of Diabetic Retinopathy. Current Diabetes Reports. 2019;19:67.
  63. Kuo JZ, Wong TY, Rotter JI. Challenges in elucidating the genetics of diabetic retinopathy. JAMA Ophthalmol. 2014;132:96–107. · DOI
  64. Klaassen I, Van Noorden CJ, Schlingemann RO. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res. 2013;34:19–48. · DOI · Paper page
  65. Simo R, Hernandez C. Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends Endocrinol Metab. 2014;25:23–33. · DOI · Paper page
  66. Simo R, Hernandez C. Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence. Prog Retin Eye Res. 2015;48:160–80. · DOI · Paper page
  67. Abcouwer SF, Gardner TW. Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment: Neuroretinal adaptation in diabetic retinopathy. Annals of the New York Academy of Sciences. 2014;1311:174–90. · DOI · Paper page
  68. Jindal V. Neurodegeneration as a primary change and role of neuroprotection in diabetic retinopathy. Mol Neurobiol. 2015;51:878–84. · DOI
  69. Barber AJ. Diabetic retinopathy: recent advances towards understanding neurodegeneration and vision loss. Sci China Life Sci. 2015;58:541–9. · doi:10.1007/s11427-015-4856-x
  70. van Dijk HW, Verbraak FD, Kok PH, Garvin MK, Sonka M, Lee K, et al. Decreased retinal ganglion cell layer thickness in patients with type 1 diabetes. Invest Ophthalmol Vis Sci. 2010;51:3660–5. · DOI · Paper page
  71. Park HY, Kim IT, Park CK. Early diabetic changes in the nerve fibre layer at the macula detected by spectral domain optical coherence tomography. Br J Ophthalmol. 2011;95:1223–8. · doi:10.1136/bjo.2010.191841
  72. Verma A, Raman R, Vaitheeswaran K, Pal SS, Laxmi G, Gupta M, et al. Does neuronal damage precede vascular damage in subjects with type 2 diabetes mellitus and having no clinical diabetic retinopathy? Ophthalmic Res. 2012;47:202–7. · DOI
  73. Vujosevic S, Midena E. Retinal layers changes in human preclinical and early clinical diabetic retinopathy support early retinal neuronal and Muller cells alterations. J Diabetes Res. 2013;2013:905058.
  74. Sohn EH, van Dijk HW, Jiao C, Kok PH, Jeong W, Demirkaya N, et al. Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus. Proc Natl Acad Sci U S A. 2016;113:E2655–2664.
  75. Santos AR, Ribeiro L, Bandello F, Lattanzio R, Egan C, Frydkjaer-Olsen U, et al. Functional and Structural Findings of Neurodegeneration in Early Stages of Diabetic Retinopathy: Cross-sectional Analyses of Baseline Data of the EUROCONDOR Project. Diabetes. 2017;66:2503–10. · DOI
  76. Chhablani J, Sharma A, Goud A, Peguda HK, Rao HL, Begum VU, et al. Neurodegeneration in Type 2 Diabetes: Evidence From Spectral-Domain Optical Coherence Tomography. Investigative Opthalmology & Visual Science. 2015;56:6333. · DOI · Paper page
  77. Hidayat AA, Fine BS. Diabetic Choroidopathy. Ophthalmology. 1985;92:512–22. · DOI · Paper page
  78. Bischoff PM, Flower RW. Ten years experience with choroidal angiography using indocyanine green dye: a new routine examination or an epilogue? Documenta Ophthalmologica. 1985;60:235–91. · DOI · Paper page
  79. Fryczkowski AW, Hodes BL, Walker J. Diabetic choroidal and iris vasculature scanning electron microscopy findings. International Ophthalmology. 1989;13:269–79. · doi:10.1007/bf02280087
  80. Ishibashi T, Murata T, Kohno T, Ohnishi Y, Inomata H. Peripheral Choriovitreal Neovascularization in Proliferative Diabetic Retinopathy: Histopathologic and Ultrastructural Study. Ophthalmologica. 1999;213:154–8. · DOI
  81. Vujosevic S, Martini F, Cavarzeran F, Pilotto E, Midena E. Macular and peripapillary choroidal thickness in diabetic patients. Retina. 2012;32:1781–90. · doi:10.1097/iae.0b013e31825db73d
  82. Yazgan S, Arpaci D, Celik HU, Dogan M, Isik I. Macular Choroidal Thickness May Be the Earliest Determiner to Detect the Onset of Diabetic Retinopathy in Patients with Prediabetes: A Prospective and Comparative Study. Curr Eye Res. 2017;42:1039–47. · DOI
  83. Kim JT, Lee DH, Joe SG, Kim JG, Yoon YH. Changes in choroidal thickness in relation to the severity of retinopathy and macular edema in type 2 diabetic patients. Invest Ophthalmol Vis Sci. 2013;54:3378–84. · DOI · Paper page
  84. Gupta C, Tan R, Mishra C, Khandelwal N, Raman R, Kim R, et al. Choroidal structural analysis in eyes with diabetic retinopathy and diabetic macular edema—A novel OCT based imaging biomarker. PLoS One. 2018;13:e0207435. · doi:10.1371/journal.pone.0207435
  85. Wang JC, Lains I, Providencia J, Armstrong GW, Santos AR, Gil P, et al. Diabetic Choroidopathy: Choroidal Vascular Density and Volume in Diabetic Retinopathy With Swept-Source Optical Coherence Tomography. Am J Ophthalmol. 2017;184:75–83. · DOI
  86. Rewbury R, Want A, Varughese R, Chong V. Subfoveal choroidal thickness in patients with diabetic retinopathy and diabetic macular oedema. Eye (Lond). 2016;30:1568–72. · DOI
  87. Adhi M, Brewer E, Waheed NK, Duker JS. Analysis of Morphological Features and Vascular Layers of Choroid in Diabetic Retinopathy Using Spectral-Domain Optical Coherence Tomography. JAMA Ophthalmology. 2013;131:1267. · DOI · Paper page
  88. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414–31. · DOI · Paper page
  89. Lorenzi M, Cagliero E, Toledo S. Glucose toxicity for human endothelial cells in culture. Delayed replication, disturbed cell cycle, and accelerated death. Diabetes. 1985;34:621–7. · DOI · Paper page
  90. Lorenzi M, Montisano DF, Toledo S, Barrieux A. High glucose induces DNA damage in cultured human endothelial cells. J Clin Invest. 1986;77:322–5. · DOI · Paper page
  91. Engerman R, Finkelstein D, Aguirre G, Diddie KR, Fox RR, Frank RN, et al. Ocular Complications. Diabetes. 1982;31(Suppl 1):82–88. · doi:10.2337/diab.31.1.s82
  92. Engerman RL. Animal models of diabetic retinopathy. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1976;81(4 Pt 1):Op710–715.
  93. Johnson MW. Etiology and treatment of macular edema. Am J Ophthalmol. 2009;147:11–21.e11. · DOI · Paper page
  94. Calles-Escandon J, Cipolla M. Diabetes and Endothelial Dysfunction: A Clinical Perspective. Endocrine Reviews. 2001;22:36–52. · DOI · Paper page
  95. Ciulla TA, Amador AG, Zinman B. Diabetic Retinopathy and Diabetic Macular Edema: Pathophysiology, screening, and novel therapies. Diabetes Care. 2003;26:2653–64. · DOI · Paper page
  96. Curtis TM, Gardiner TA, Stitt AW. Microvascular lesions of diabetic retinopathy: clues towards understanding pathogenesis? Eye. 2009;23:1496–508. · DOI · Paper page
  97. Amoaku WM, Saker S, Stewart EA. A review of therapies for diabetic macular oedema and rationale for combination therapy. Eye (Lond). 2015;29:1115–30. · DOI
  98. Brownlee M. The Pathobiology of Diabetic Complications: A Unifying Mechanism. Diabetes. 2005;54:1615–25. · DOI · Paper page
  99. Morigi M, Angioletti S, Imberti B, Donadelli R, Micheletti G, Figliuzzi M, et al. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. J Clin Invest. 1998;101:1905–15. · DOI · Paper page
  100. Booth G, Stalker TJ, Lefer AM, Scalia R. Mechanisms of Amelioration of Glucose-Induced Endothelial Dysfunction Following Inhibition of Protein Kinase C In Vivo. Diabetes. 2002;51:1556–64. · DOI
  101. Omi H, Okayama N, Shimizu M, Okouchi M, Ito S, Fukutomi T, et al. Participation of high glucose concentrations in neutrophil adhesion and surface expression of adhesion molecules on cultured human endothelial cells: effect of antidiabetic medicines. J Diabetes Complications. 2002;16:201–8. · DOI
  102. Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature. 1995;376:517–9. · DOI · Paper page
  103. Miyamoto K, Ogura Y. Pathogenetic potential of leukocytes in diabetic retinopathy. Semin Ophthalmol. 1999;14:233–9. · doi:10.3109/08820539909069542
  104. Chibber R, Ben-Mahmud B, Chibber S, Kohner E. Leukocytes in Diabetic Retinopathy. Current Diabetes Reviews. 2007;3:3–14. · DOI · Paper page
  105. Chibber R, Ben-Mahmud BM, Coppini D, Christ E, Kohner EM. Activity of the glycosylating enzyme, core 2 GlcNAc (beta1,6) transferase, is higher in polymorphonuclear leukocytes from diabetic patients compared with age-matched control subjects: relevance to capillary occlusion in diabetic retinopathy. Diabetes. 2000;49:1724–30. · DOI
  106. Chibber R, Ben-Mahmud BM, Mann GE, Zhang JJ, Kohner EM. Protein Kinase C 2-Dependent Phosphorylation of Core 2 GlcNAc-T Promotes Leukocyte-Endothelial Cell Adhesion: A Mechanism Underlying Capillary Occlusion in Diabetic Retinopathy. Diabetes. 2003;52:1519–27. · DOI
  107. Kaji Y, Usui T, Ishida S, Yamashiro K, Moore TC, Moore J, et al. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci. 2007;48:858–65. · DOI
  108. Rangasamy S, Srinivasan R, Maestas J, McGuire PG, Das A. A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2011;52:3784–91. · DOI · Paper page
  109. Yoshimura T, Sonoda KH, Sugahara M, Mochizuki Y, Enaida H, Oshima Y, et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One. 2009;4:e8158. · DOI · Paper page
  110. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. Faseb j. 2004;18:1450–2. · DOI · Paper page
  111. Kim SJ, Equi R, Bressler NM. Analysis of Macular Edema after Cataract Surgery in Patients with Diabetes Using Optical Coherence Tomography. Ophthalmology. 2007;114:881–9. · DOI · Paper page
  112. Kim YM, Kim YM, Lee YM, Kim HS, Kim JD, Choi Y, et al. TNF-related activation-induced cytokine (TRANCE) induces angiogenesis through the activation of Src and phospholipase C (PLC) in human endothelial cells. J Biol Chem. 2002;277:6799–805. · DOI
  113. Kita T, Clermont AC, Murugesan N, Zhou Q, Fujisawa K, Ishibashi T, et al. Plasma Kallikrein-Kinin System as a VEGF-Independent Mediator of Diabetic Macular Edema. Diabetes. 2015;64:3588–99. · DOI
  114. Min JK, Cho YL, Choi JH, Kim Y, Kim JH, Yu YS, et al. Receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) increases vascular permeability: impaired permeability and angiogenesis in eNOS-deficient mice. Blood. 2007;109:1495–502. · DOI
  115. Roh MI, Kim HS, Song JH, Lim JB, Kwon OW. Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema. Ophthalmology. 2009;116:80–86. · DOI
  116. Funk M, Schmidinger G, Maar N, Bolz M, Benesch T, Zlabinger GJ, et al. Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab. Retina. 2010;30:1412–9. · DOI
  117. Sohn HJ, Han DH, Kim IT, Oh IK, Kim KH, Lee DY, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol. 2011;152:686–94. · DOI · Paper page
  118. Funatsu H, Yamashita H, Ikeda T, Nakanishi Y, Kitano S, Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. American Journal of Ophthalmology. 2002;133:537–43. · DOI · Paper page
  119. Funatsu H, Yamashita H, Sakata K, Noma H, Mimura T, Suzuki M, et al. Vitreous Levels of Vascular Endothelial Growth Factor and Intercellular Adhesion Molecule 1 Are Related to Diabetic Macular Edema. Ophthalmology. 2005;112:806–16. · DOI · Paper page
  120. Funatsu H, Yamashita H, Shimizu E, Kojima R, Hori S. Relationship between vascular endothelial growth factor and interleukin–6 in diabetic retinopathy. Retina. 2001;21:469–77. · DOI
  121. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med. 2000;6:460–3. · DOI · Paper page
  122. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, et al. Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning. Cell. 1996;87:1161–9. · DOI · Paper page
  123. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277:55–60. · DOI · Paper page
  124. Koehne P, Willam C, Strauss E, Schindler R, Eckardt KU, Buhrer C. Lack of hypoxic stimulation of VEGF secretion from neutrophils and platelets. Am J Physiol Heart Circ Physiol. 2000;279:H817–824. · DOI
  125. Eklund L, Saharinen P. Angiopoietin signaling in the vasculature. Experimental Cell Research. 2013;319:1271–80. · DOI · Paper page
  126. Yao D, Taguchi T, Matsumura T, Pestell R, Edelstein D, Giardino I, et al. High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. J Biol Chem. 2007;282:31038–45. · DOI · Paper page
  127. Patel JI, Hykin PG, Gregor ZJ, Boulton M, Cree IA. Angiopoietin concentrations in diabetic retinopathy. Br J Ophthalmol. 2005;89:480–3. · DOI
  128. Peters S, Cree IA, Alexander R, Turowski P, Ockrim Z, Patel J, et al. Angiopoietin modulation of vascular endothelial growth factor: Effects on retinal endothelial cell permeability. Cytokine. 2007;40:144–50. · DOI
  129. Pfister F, Wang Y, Schreiter K, vom Hagen F, Altvater K, Hoffmann S, et al. Retinal overexpression of angiopoietin-2 mimics diabetic retinopathy and enhances vascular damages in hyperglycemia. Acta Diabetol. 2010;47:59–64. · DOI
  130. Watanabe D, Suzuma K, Suzuma I, Ohashi H, Ojima T, Kurimoto M, et al. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2005;139:476–81. · DOI · Paper page
  131. Hackett SF, Ozaki H, Strauss RW, Wahlin K, Suri C, Maisonpierre P, et al. Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization. J Cell Physiol. 2000;184:275–84. · DOI · Paper page
  132. Stewart EA, Saker S, Amoaku WM. Dexamethasone reverses the effects of high glucose on human retinal endothelial cell permeability and proliferation in vitro. Exp Eye Res. 2016;151:75–81. · DOI
  133. Abdouh M, Talbot S, Couture R, Hasséssian HM. Retinal plasma extravasation in streptozotocin-diabetic rats mediated by kinin B1 and B2 receptors. British Journal of Pharmacology. 2008;154:136–43. · doi:10.1038/bjp.2008.48
  134. Clermont A, Chilcote TJ, Kita T, Liu J, Riva P, Sinha S, et al. Plasma Kallikrein Mediates Retinal Vascular Dysfunction and Induces Retinal Thickening in Diabetic Rats. Diabetes. 2011;60:1590–8. · DOI
  135. Gao B-B, Clermont A, Rook S, Fonda SJ, Srinivasan VJ, Wojtkowski M, et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nature Medicine. 2007;13:181–8. · DOI · Paper page
  136. Wise GN. Retinal neovascularization. Trans Am Ophthalmol Soc. 1956;54:729–826.
  137. Ashton N. Pathological basis of retrolental fibroplasia. Br J Ophthalmol. 1954;38:385–96. · doi:10.1136/bjo.38.7.385
  138. Browning AC, Alibhai A, McIntosh RS, Rotchford AP, Bhan A, Amoaku WM. Effect of diabetes mellitus and hyperglycemia on the proliferation of human Tenon's capsule fibroblasts: Implications for wound healing after glaucoma drainage surgery. Wound Repair and Regeneration. 2005;13:295–302. · doi:10.1111/j.1067-1927.2005.00130312.x
  139. Kolluru GK, Bir SC, Kevil CG. Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. Int J Vasc Med. 2012;2012:918267.
  140. Jain M, LoGerfo FW, Guthrie P, Pradhan L. Effect of hyperglycemia and neuropeptides on interleukin-8 expression and angiogenesis in dermal microvascular endothelial cells. J Vasc Surg. 2011;53:1654–1660.e1652. · DOI
  141. Adamis AP, Miller JW, Bernal M-T, D'Amico DJ, Folkman J, Yeo T-K, et al. Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes With Proliferative Diabetic Retinopathy. American Journal of Ophthalmology. 1994;118:445–50. · DOI · Paper page
  142. Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AEB, Al-Shabrawey M, Platt DH, et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes/Metabolism Research and Reviews. 2003;19:442–55. · DOI · Paper page
  143. Shima DT, Adamis AP, Ferrara N, Yeo KT, Yeo TK, Allende R, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med. 1995;1:182–93. · DOI · Paper page
  144. Simo R, Lecube A, Segura RM, Garcia Arumi J, Hernandez C. Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2002;134:376–82. · doi:10.1016/s0002-9394(02)01538-6
  145. D'Amore PA. Vascular endothelial cell growth factor-a: not just for endothelial cells anymore. Am J Pathol. 2007;171:14–18. · DOI
  146. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007;171:53–67. · DOI · Paper page
  147. Simo R, Carrasco E, Garcia-Ramirez M, Hernandez C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev. 2006;2:71–98. · DOI · Paper page
  148. Klaassen I, de Vries EW, Vogels IMC, van Kampen AHC, Bosscha MI, Steel DHW, et al. Identification of proteins associated with clinical and pathological features of proliferative diabetic retinopathy in vitreous and fibrovascular membranes. PLoS One. 2017;12:e0187304. · DOI
  149. Murugeswari P, Shukla D, Rajendran A, Kim R, Namperumalsamy P, Muthukkaruppan V. Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales' disease. Retina. 2008;28:817–24. · DOI · Paper page
  150. Sivaprasad S, Pearce E. The unmet need for better risk stratification of non-proliferative diabetic retinopathy. Diabet Med. 2019;36:424–33. · DOI
  151. Ghanchi F. Diabetic Retinopathy Guidelines Working G. The Royal College of Ophthalmologists' clinical guidelines for diabetic retinopathy: a summary. Eye (Lond). 2013;27:285–7. · doi:10.1038/eye.2012.287
  152. Shin HJ, Lee SH, Chung H, Kim HC. Association between photoreceptor integrity and visual outcome in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2012;250:61–70. · DOI · Paper page
  153. Sun JK, Lin MM, Lammer J, Prager S, Sarangi R, Silva PS, et al. Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. JAMA Ophthalmol. 2014;132:1309–16. · DOI · Paper page
  154. Rayess N, Rahimy E, Ying GS, Bagheri N, Ho AC, Regillo CD, et al. Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema. Am J Ophthalmol. 2015;159:85–91.e81-83 · doi:10.1016/j.ajo.2014.09.033
  155. Tan CS, Chew MC, Lim LW, Sadda SR. Advances in retinal imaging for diabetic retinopathy and diabetic macular edema. Indian J Ophthalmol. 2016;64:76–83. · DOI
  156. Muqit MM, Gray JC, Marcellino GR, Henson DB, Young LB, Patton N, et al. Barely visible 10-millisecond pascal laser photocoagulation for diabetic macular edema: observations of clinical effect and burn localization. Am J Ophthalmol. 2010;149:979–986.e972 · doi:10.1016/j.ajo.2010.01.032
  157. Vujosevic S, Martini F, Longhin E, Convento E, Cavarzeran F, Midena E. Subthreshold micropulse yellow laser versus subthreshold micropulse infrared laser in center-involving diabetic macular edema: Morphologic and Functional Safety. Retina. 2015;35:1594–603. · doi:10.1097/iae.0000000000000521
  158. Vujosevic S, Bottega E, Casciano M, Pilotto E, Convento E, Midena E. Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation. Retina. 2010;30:908–16. · doi:10.1097/iae.0b013e3181c96986
  159. Schwartz R, Khalid H, Sivaprasad S, Nicholson L, Anikina E, Sullivan P, et al. Objective evaluation of proliferative diabetic retinopathy using OCT. Ophthalmol Retina. 2020;4:164–74. · doi:10.1016/j.oret.2019.09.004
  160. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabetic medicine : a journal of the British Diabetic Association. 2012;29:855–62. · DOI · Paper page
  161. Seidu S, Davies MJ, Farooqi A, Khunti K. Integrated primary care: is this the solution to the diabetes epidemic? Diabetic medicine : a journal of the British Diabetic Association. 2017;34:748–50. · DOI
  162. Olafsdottir E, Andersson DK, Dedorsson I, Stefansson E. The prevalence of retinopathy in subjects with and without type 2 diabetes mellitus. Acta Ophthalmol. 2014;92:133–7. · DOI
  163. Looker HC, Nyangoma SO, Cromie D, Olson JA, Leese GP, Black M, et al. Diabetic retinopathy at diagnosis of type 2 diabetes in Scotland. Diabetologia. 2012;55:2335–42. · DOI
  164. Lindenmeyer A, Sturt JA, Hipwell A, Stratton IM, Al-Athamneh N, Gadsby R, et al. Influence of primary care practices on patients' uptake of diabetic retinopathy screening: a qualitative case study. Br J Gen Pract. 2014;64:e484–492. · DOI
  165. Ting DS, Cheung GC, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol. 2016;44:260–77. · DOI · Paper page
  166. Wang B, Wang F, Zhang Y, Zhao SH, Zhao WJ, Yan SL, et al. Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis. The lancet Diabetes & endocrinology. 2015;3:263–74. · DOI
  167. Action to Control Cardiovascular Risk in Diabetes Follow-On Eye Study G, the Action to Control Cardiovascular Risk in Diabetes Follow-On Study G. Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study. Diabetes Care. 2016;39:1089–1100. · DOI · Paper page
  168. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370:1687–97. · DOI · Paper page
  169. Shi R, Zhao L, Wang F, Liu F, Chen Z, Li R, et al. Effects of lipid-lowering agents on diabetic retinopathy: a Meta-analysis and systematic review. Int J Ophthalmol. 2018;11:287–95.
  170. Khunti K, Gadsby R, Millett C, Majeed A, Davies M. Quality of diabetes care in the UK: comparison of published quality-of-care reports with results of the Quality and Outcomes Framework for Diabetes. Diabetic medicine : a journal of the British Diabetic Association. 2007;24:1436–41. · DOI
  171. Hamid A, Wharton HM, Mills A, Gibson JM, Clarke M, Dodson PM. Diagnosis of retinopathy in children younger than 12 years of age: implications for the diabetic eye screening guidelines in the UK. Eye (Lond). 2016;30:949–51. · doi:10.1038/eye.2016.59
  172. Scanlon PH, Stratton IM, Bachmann MO, Jones C, Leese GP. Four Nations Diabetic Retinopathy Screening Study G. Risk of diabetic retinopathy at first screen in children at 12 and 13 years of age. Diabet Med. 2016;33:1655–8. · DOI
  173. International Diabetes Federation. IDF Atlas, 6th Edition. 2013. https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/19-atlas-6thedition.html.
  174. Rasmussen KL, Laugesen CS, Ringholm L, Vestgaard M, Damm P, Mathiesen ER. Progression of diabetic retinopathy during pregnancy in women with type 2 diabetes. Diabetologia. 2010;53:1076–83. · DOI
  175. Axer-Siegel R, Hod M, Fink-Cohen S, Kramer M, Weinberger D, Schindel B, et al. Diabetic Retinopathy during Pregnancy. Ophthalmology. 1996;103:1815–9. · DOI
  176. Chew EY, Mills JL, Metzger BE, Remaley NA, Jovanovic-Peterson L, Knopp RH, et al. Metabolic Control and Progression of Retinopathy: The Diabetes in Early Pregnancy Study. Diabetes Care. 1995;18:631–7. · DOI · Paper page
  177. Dibble CM, Kochenour NK, Worley RJ, Tyler FH, Swartz M. Effect of pregnancy on diabetic retinopathy. Obstetrics and gynecology. 1982;59:699–704.
  178. Klein BE, Moss SE, Klein R. Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care. 1990;13:34–40. · DOI · Paper page
  179. Phelps RL, Sakol P, Metzger BE, Jampol LM, Freinkel N. Changes in diabetic retinopathy during pregnancy. Correlations with regulation of hyperglycemia. Arch Ophthalmol. 1986;104:1806–10. · DOI
  180. Rahman W, Rahman FZ, Yassin S, Al-Suleiman SA, Rahman J. Progression of retinopathy during pregnancy in type 1 diabetes mellitus. Clin Exp Ophthalmol. 2007;35:231–6. · DOI
  181. Temple RC, Aldridge VA, Sampson MJ, Greenwood RH, Heyburn PJ, Glenn A. Impact of pregnancy on the progression of diabetic retinopathy in Type 1 diabetes. Diabet Med. 2001;18:573–7. · DOI
  182. Moloney JB, Drury MI. The effect of pregnancy on the natural course of diabetic retinopathy. Am J Ophthalmol. 1982;93:745–56. · DOI · Paper page
  183. Joseph SE, McHugh D, Blott M, Amiel SA, Watkins PJ. Acceleration of diabetic retinopathy in pregnancy: a case report. Diabet Med. 2001;18:675–8. · doi:10.1046/j.1464-5491.2001.00525.x
  184. Egan AM, McVicker L, Heerey A, Carmody L, Harney F, Dunne FP. Diabetic Retinopathy in Pregnancy: A Population-Based Study of Women with Pregestational Diabetes. Journal of Diabetes Research. 2015;2015:1–7. · DOI
  185. Lovestam-Adrian M, Agardh CD, Aberg A, Agardh E. Pre-eclampsia is a potent risk factor for deterioration of retinopathy during pregnancy in Type 1 diabetic patients. Diabet Med. 1997;14:1059–65. · doi:10.1002/(sici)1096-9136(199712)14:12<1059::aid-dia505>3.0.co;2-8
  186. Association AD. 12. Management of Diabetes in Pregnancy. Diabetes Care. 2015;38(Supplement_1):S77–S79. · DOI
  187. Helen CC, Tajunisah I, Reddy SC. Adverse outcomes in Type I diabetic pregnant women with proliferative diabetic retinopathy. Int J Ophthalmol. 2011;4:443–6.
  188. Kohner EM. Microvascular disease: what does the UKPDS tell us about diabetic retinopathy? Diabet Med. 2008;25(Suppl 2):20–24. · DOI
  189. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet (London, England). 2010;376:631–44. · DOI · Paper page
  190. Atkins AFJ, Watt JM, Milan P, Davies P, Crawford JS. A longitudinal study of cardiovascular dynamic changes throughout pregnancy. European Journal of Obstetrics & Gynecology and Reproductive Biology. 1981;12:215–24. · doi:10.1016/0028-2243(81)90012-5
  191. Chen HC, Newsom RS, Patel V, Cassar J, Mather H, Kohner EM. Retinal blood flow changes during pregnancy in women with diabetes. Invest Ophthalmol Vis Sci. 1994;35:3199–208.
  192. Tooke JE. Microvascular function in human diabetes. A physiological perspective. Diabetes. 1995;44:721–6. · DOI · Paper page
  193. Best RM, Chakravarthy U. Diabetic retinopathy in pregnancy. British Journal of Ophthalmology. 1997;81:249–51. · DOI
  194. Schocket LS, Grunwald JE, Tsang AF, DuPont J. The effect of pregnancy on retinal hemodynamics in diabetic versus nondiabetic mothers. Am J Ophthalmol. 1999;128:477–84. · doi:10.1016/s0002-9394(99)00234-2
  195. Kitzmiller JL, Main E, Ward B, Theiss T, Peterson DL. Insulin lispro and the development of proliferative diabetic retinopathy during pregnancy. Diabetes Care. 1999;22:874–6. · DOI
  196. Lauszus FF, Klebe JG, Bek T, Flyvbjerg A. Increased serum IGF-I during pregnancy is associated with progression of diabetic retinopathy. Diabetes. 2003;52:852–6. · DOI
  197. Ringholm L, Vestgaard M, Laugesen CS, Juul A, Damm P, Mathiesen ER. Pregnancy-induced increase in circulating IGF-I is associated with progression of diabetic retinopathy in women with type 1 diabetes. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2011;21:25–30. · DOI
  198. Arun CS, Taylor R. Influence of pregnancy on long-term progression of retinopathy in patients with type 1 diabetes. Diabetologia. 2008;51:1041–5. · DOI
  199. Serup L. Influence of pregnancy on diabetic retinopathy. Acta endocrinologica Supplementum. 1986;277:122–4.
  200. Soubrane G, Canivet J, Coscas G. Influence of pregnancy on the evolution of background retinopathy. Preliminary results of a prospective fluorescein angiography study. Int Ophthalmol. 1985;8:249–55. · doi:10.1007/bf00137653

200 of 441 shown

Cited by

See all 216

Metadata

Authors
Amoaku, W. M., Ghanchi, F., Bailey, C., Banerjee, S., Banerjee, S., Downey, L., Gale, R., Hamilton, R., Khunti, K., Posner, E., Quhill, F., Robinson, S., Setty, R., Sim, D., Varma, D., & Mehta, H.
Venue
Eye
Published
2020-06
Volume
34
Issue
S1
Pages
1-51
ISSN
  • 0078-5334 (ISSN-L)
  • 0950-222X
  • 1476-5454
OpenAlex
W3033336739
Cited by
216
References
27
FWCI
18.81
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. https://app.cochat.ai/papers/10.1038/s41433-020-0961-6
The paper
Amoaku, W. M., Ghanchi, F., Bailey, C., Banerjee, S., Banerjee, S., Downey, L., Gale, R., Hamilton, R., Khunti, K., Posner, E., Quhill, F., Robinson, S., Setty, R., Sim, D., Varma, D., & Mehta, H. (2020). Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. Eye. https://doi.org/10.1038/s41433-020-0961-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.